A Study to Compare Denosumab With Zoledronic Acid in Subjects With Bone Metastases From Solid Tumors

NCT01920568 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

487

Enrollment

INDUSTRY

Sponsor class

Conditions

Fractures, Bone

Interventions

BIOLOGICAL: Denosumab 70 mg/mL
DRUG: Zoledronic acid 4 mg
DRUG: Placebo IV
DRUG: Placebo SC
DIETARY_SUPPLEMENT: Calcium supplement
DIETARY_SUPPLEMENT: Vitamin D supplement

Sponsor

GlaxoSmithKline

Collaborators

[object Object]